Edition:
India

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

4.98EUR
7 Aug 2020
Change (% chg)

€0.16 (+3.32%)
Prev Close
€4.82
Open
€4.73
Day's High
€5.07
Day's Low
€4.72
Volume
147,340
Avg. Vol
167,976
52-wk High
€10.64
52-wk Low
€2.75

Latest Key Developments (Source: Significant Developments)

Biocartis Group Says Idylla™ Allows Rapid and Accurate Mutation Testing Results
Friday, 26 Jun 2020 

June 26 (Reuters) - BIOCARTIS GROUP NV ::US MULTICENTER STUDY SHOWS IDYLLA™ ALLOWS RAPID AND ACCURATE MUTATION TESTING RESULTS ACROSS DIFFERENT LABORATORY SETTINGS.STUDY SHOWS THAT, COMPARED TO CURRENT STANDARD-OF-CARE TESTING METHODS, BIOCARTIS' IDYLLA™ CAN SUBSTANTIALLY IMPROVE TURNAROUND TIME OF RESULTS OF MUTATION TESTING.RESEARCHERS FOUND THAT AVERAGE TURNAROUND TIME FOR TEST RESULTS COULD BE CUT BY MORE THAN 50% FROM 15 DAYS TO 5 DAYS, WITH SOME RESULTS AVAILABLE IN A SINGLE DAY, WITH IDYLLA.  Full Article

Biocartis Creates New Share Option Plan
Thursday, 30 Apr 2020 

April 30 (Reuters) - Biocartis Group NV ::BIOCARTIS CREATES NEW SHARE OPTION PLAN.ANNOUNCES TODAY THAT ITS BOARD OF DIRECTORS CREATED, WITHIN FRAMEWORK OF AUTHORIZED CAPITAL, 860,000 SHARE OPTIONS.SHARE OPTIONS UNDER SHARE OPTION PLAN 2020B HAVE A TERM OF TEN YEARS.SHARE OPTION AS SUCH WILL NOT BE LISTED ON ANY STOCK MARKET.SHOULD SHARE OPTIONS BE EXERCISED, BIOCARTIS WILL APPLY FOR ADMISSION TO TRADING OF RESULTING NEW SHARES ON EURONEXT BRUSSELS.  Full Article

Biocartis Suspends Guidance, Appoints New CFO
Thursday, 23 Apr 2020 

April 23 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS Q1 2020 BUSINESS UPDATE.BIOCARTIS' CASH POSITION END Q1 2020 AMOUNTED TO EUR 170.1M.SLOWER THAN EXPECTED INSTALLED BASE EXPANSION ACROSS MARKETS IN Q1 2020 DUE TO GLOBAL COVID-19 PANDEMIC.APPOINTMENT NEW CFO: BIOCARTIS ANNOUNCES APPOINTMENT OF JEAN-MARC ROELANDT AS NEW CHIEF FINANCIAL OFFICER ('CFO').COMPANY IS SUSPENDING ITS GUIDANCE ON INSTRUMENT PLACEMENTS IN 2020 AND WILL PROVIDE AN UPDATE AS SOON AS NORMAL BUSINESS ACTIVITY RESUMES.ON CORONAVIRUS: DUE TO COVID-19 PANDEMIC, NEW IDYLLA™ INSTRUMENT PLACEMENTS SLOWED DOWN TOWARDS END Q1 2020 AS ACCESS TO HOSPITALS WAS RESTRICTED.BIOCARTIS SEES POTENTIAL TO STILL MEET ITS 2020 COMMERCIAL CARTRIDGE VOLUME OBJECTIVE.HOWEVER GIVEN CURRENT UNCERTAINTIES AROUND TIMING OF NORMALIZATION, COMPANY CURRENTLY ALSO SUSPENDS GUIDANCE ON COMMERCIAL CARTRIDGE VOLUME GROWTH.CASH POSITION IS STILL TARGETED TO BE IN RANGE OF EUR 110M BY YEAR-END 2020..  Full Article

Biocartis Announces Co-Commercialisation Agreement For SeptiCyte RAPID Test
Thursday, 26 Mar 2020 

March 26 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS ANNOUNCES CO-COMMERCIALIZATION OF THE SEPTICYTE® RAPID TEST ON IDYLLA™ (CE-IVD) AND PROVIDES UPDATE ON COVID-19 IMPACT.COVID-19: EXPECTS THAT CURRENT PROLONGED MEASURES TAKEN IN MANY COUNTRIES ACROSS GLOBE MAY POTENTIALLY IMPACT FY 2020 OUTLOOK OF COMPANY.  Full Article

Biocartis Group FY Total Operating Income Up At 37.7 Million Euros
Thursday, 5 Mar 2020 

March 5 (Reuters) - BIOCARTIS GROUP NV ::FY TOTAL OPERATING INCOME EUR 37.7 MILLION VERSUS EUR 28.7 MILLION YEAR AGO.ANNOUNCES 2019 RESULTS AND 2020 OUTLOOK.ON CORONAVIRUS: IMPACT COVID-19 OUTBREAK: GUIDANCE FOR 2020 ASSUMES A MODERATE IMPACT OF ONGOING WORLDWIDE COVID-19 OUTBREAK.TARGETED CASH POSITION IN RANGE OF EUR 110M BY 2020 YEAR END.SEES 2020 COMMERCIAL CARTRIDGE VOLUME: TARGETING A YEAR-OVER-YEAR COMMERCIAL VOLUME GROWTH IN RANGE OF 30%.SEES 2020 INSTALLED BASE: TARGETING AN INSTALLED BASE GROWTH IN RANGE OF 300-350 NEW INSTRUMENT PLACEMENTS..FY NET LOSS EUR 64.1 MILLION VERSUS LOSS OF EUR 48.2 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 179M AS PER 31 DECEMBER 2019.FY TOTAL PRODUCT SALES INCREASED YEAR-OVER-YEAR WITH 29% TO EUR 24.2M IN 2019 (EUR 18.8M IN 2018).  Full Article

Biocartis: New Immuno-Oncology Project With Bristol-Myers Squibb
Thursday, 5 Mar 2020 

March 5 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS ANNOUNCES NEW IMMUNO-ONCOLOGY PROJECT WITH BRISTOL-MYERS SQUIBB AIMED AT REGISTRATION OF IDYLLA™ MSI TEST IN CHINA.BRISTOL-MYERS SQUIBB AND BIOCARTIS HAVE NOW AGREED TO ADD A NEW PROJECT UNDER THEIR COLLABORATION.NEW PROJECT PURSUES REGISTRATION OF IDYLLA™ MSI TEST AS A CDX TEST IN MCRC IN PEOPLE'S REPUBLIC OF CHINA.BIOCARTIS GROUP NV - BIOCARTIS' JV WONDFO-CARTIS WILL COMMERCIALIZE IDYLLA MSI TEST IN CHINA UPON OBTAINING REGULATORY APPROVAL.  Full Article

Biocartis Creates New Share Option Plan
Thursday, 5 Mar 2020 

March 5 (Reuters) - Biocartis Group NV ::REG-PRESS RELEASE BIOCARTIS GROUP NV: BIOCARTIS CREATES NEW SHARE OPTION PLAN & CANCELS OUTSTANDING POOL UNDER 2018 SHARE OPTION PLAN.  Full Article

Biocartis Announces Achievement Of Its 2019 Objectives
Thursday, 9 Jan 2020 

Jan 9 (Reuters) - Biocartis Group NV ::BIOCARTIS MEETS 2019 KEY BUSINESS OBJECTIVES.CASH POSITION - AS PER 31 DECEMBER 2019, BIOCARTIS' CASH POSITION AMOUNTED TO EUR 179M (NON-AUDITED NUMBER) VERSUS LATEST GUIDANCE OF EUR 170-175M.WE ACHIEVED OUR 2019 OBJECTIVES IN LINE WITH LATEST GUIDANCE THAT WE ISSUED IN SEPTEMBER - CEO.CARTRIDGE VOLUME - IN 2019, BIOCARTIS REALIZED A COMMERCIAL VOLUME OF 175K CARTRIDGES.INSTALLED BASE: BIOCARTIS REALIZED 337 NEW INSTRUMENT PLACEMENTS IN 2019.PERFORMANCE THAT WE HAVE SEEN IN US IN Q4 IS ENCOURAGING AND INDICATES THAT IMPLEMENTATION OF OUR NEW GO-TO MARKET STRATEGY IS ON TRACK TO FURTHER DRIVE COMMERCIALIZATION IN THAT MARKET - CEO.  Full Article

Biocartis Updates On EUR 150 Mln Senior Unsecured Convertible Bonds
Thursday, 14 Nov 2019 

Nov 14 (Reuters) - BIOCARTIS GROUP NV ::REG-PRESS RELEASE BIOCARTIS GROUP NV: LISTING OF THE EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024.EUR 150 MILLION 4.00% CONVERTIBLE BONDS DUE 2024 HAVE BEEN ADMITTED TO TRADING AND LISTING ON EURONEXT BRUSSELS.  Full Article

Biocartis Group Q3 Cash Position Up At 197 Million Euros
Thursday, 14 Nov 2019 

Nov 14 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS' CASH POSITION END Q3 2019 AMOUNTED TO EUR 197 MILLION.YEAR-OVER-YEAR VOLUME GROWTH OF 27% FOR Q3 2019.FULL YEAR 2019 GUIDANCE REITERATED.TARGETED CASH POSITION IN THE RANGE OF EUR 170 MLN - EUR 175 MLN BY YEAR END.  Full Article

BRIEF-Biocartis Group Says Idylla™ Allows Rapid and Accurate Mutation Testing Results

* US MULTICENTER STUDY SHOWS IDYLLA™ ALLOWS RAPID AND ACCURATE MUTATION TESTING RESULTS ACROSS DIFFERENT LABORATORY SETTINGS